1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
- Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1
- KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12
- New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13